Company intelligence / Profile preview

Precision Health Research, Singapore

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

PRECISE is actively driving the SG100K cohort project, sequencing and analyzing genomes and proteomes from over 100,000 Singaporeans across major ethnic groups to drive clinical insights in population health, with current emphasis on discovery and pilot precision medicine implementation.

Therapeutic areas: OncologyOtherEndocrinologyRare Diseases
Modalities: GenomicsPopulation genomicsProteomicsData-driven healthcare
Industry: Academic Hospital/University/Research

Partnerships

Standard BioTools (SomaScan platform collaboration)Singapore government and all major national healthcare institutes (e.g., A*STAR, National University Health System, National Healthcare Group, SingHealth Duke-NUS, Lee Kong Chian School of Medicine)Boehringer Ingelheim (research partnership)

Beyond the preview

Go deeper on Precision Health Research, Singapore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision Health Research, Singapore.

Explore the full profile